期刊
LEUKEMIA RESEARCH
卷 41, 期 -, 页码 85-95出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2015.12.005
关键词
Bortezomib; TRAF3; B lymphoma; Multiple myeloma; Noxa; Oridonin; AD 198
资金
- National Institutes of Health [CA158402]
- New Jersey Commission on Cancer Research [10-1066-CCR-EO]
- Busch Biomedical Grant
- Arthur McCallum Summer Fellowship
- Aresty Undergraduate Research Grants
- Flow Cytometry Core Facility of The Cancer Institute of New Jersey [P30CA072720]
Bortezomib, a clinical drug for multiple myeloma (MM) and mantle cell lymphoma, exhibits complex mechanisms of action, which vary depending on the cancer type and the critical genetic alterations of each cancer. Here we investigated the signaling mechanisms of bortezomib in mouse B lymphoma and human MM cells deficient in a new tumor suppressor gene, TRAF3. We found that bortezomib consistently induced up-regulation of the cell cycle inhibitor p21(WAF1) and the pro-apoptotic protein Noxa as well as cleavage of the anti-apoptotic protein Mcl-1. Interestingly, bortezomib induced the activation of NF-kappa B1 and the accumulation of the oncoprotein c-Myc, but inhibited the activation of NF-kappa B2. Furthermore, we demonstrated that oridonin (an inhibitor of NF-kappa B1 and NF -032) or AD 198 (a drug targeting c-Myc) drastically potentiated the anti-cancer effects of bortezomib in TRAF3-deficient malignant B cells. Taken together, our findings increase the understanding of the mechanisms of action of bortezomib, which would aid the design of novel bortezomib-based combination therapies. Our results also provide a rationale for clinical evaluation of the combinations of bortezomib and oridonin (or other inhibitors of NF-kappa B1/2) or AD 198 (or other drugs targeting c-Myc) in the treatment of lymphoma and MM, especially in patients containing TRAF3 deletions or relevant mutations. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据